RNA epigenetic modifications have uncovered as not only an intermediary structure between DNA and protein or an effector ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA ... of Ionis – which are developing an antisense-based candidate called pelacarsen (formerly ...

Trace is partnering with Unlearn as it advances plans for a clinical trial of its treatment candidate that targets the UNC13A ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

RNA splicing is a modification of the nascent pre-messenger RNA (pre-mRNA) transcript in which introns are removed and exons are joined prior to translation. For many eukaryotic introns, splicing ...

Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co. Ltd. (SKK) have entered an agreement to codevelop SK-2407/SN-001 for the treatment of dentatorubral-pallidoluysian atrophy (DRPLA) in Japan.

micro RNAs (miRNAs) are a type of non-coding RNA (ncRNA), ~21 24 nucleotides in length, that function in the post-transcriptional regulation of gene expression. Typically miRNAs interact with ...